Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19944470 | 0.97 | LMNA (0.43) | LMNALTA4HPPARGPPARA | |
| SCHEMBL19944372 | 0.92 | MTNR1A (0.50) | MTNR1AMTNR1BPOLBMAPTLMNA | |
| SCHEMBL9926765 | 0.89 | AR (0.45) | POLBMAPTLMNAELANEAR | |
| SCHEMBL19944473 | 0.89 | LTA4H (0.47) | MTNR1AMTNR1BPOLBMAPTLMNA | |
| SCHEMBL4197201 | 0.89 | MAPT (0.47) | MTNR1AMTNR1BPOLBMAPTLMNA | |
| SCHEMBL6883461 | 0.86 | PPARG (0.53) | MTNR1AMTNR1BLMNAARPPARG | |
| SCHEMBL17036919 | 0.86 | POLB (0.46) | MTNR1AMTNR1BPOLBMAPTAR | |
| SCHEMBL4188595 | 0.86 | MAPT (0.50) | MTNR1AMTNR1BMAPTLMNAELANE | |
| SCHEMBL11957216 | 0.86 | MTNR1A (0.46) | MTNR1AMTNR1BPOLBLMNA | |
| SCHEMBL6880397 | 0.86 | MTNR1A (0.46) | MTNR1AMTNR1BPOLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344076-B2 | Prepared by the reaction of an epoxy compound and a reactive ester; adhesive | DESIGNER MOLECULES, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344076-B2 | Prepared by the reaction of an epoxy compound and a reactive ester; adhesive | DESIGNER MOLECULES, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20080142158-A1 | HYDROLYTICALLY RESISTANT THERMOSET MONOMERS | DESIGNER MOLECULES, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080142158-A1 | HYDROLYTICALLY RESISTANT THERMOSET MONOMERS | DESIGNER MOLECULES, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080142158-A1 | HYDROLYTICALLY RESISTANT THERMOSET MONOMERS | ESD, JMJD7, PCNA | MTNR1A 2704/4885MTNR1B 1931/4885SRD5A2 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.